

## Appendix B: Stakeholder consultation comments table

### 2019 surveillance of [Developing and updating local formularies](#) (2014)

Consultation dates: 10 to 23 January 2019

Do you agree with the proposal to not to update the guideline?			
Stakeholder	Overall response	Comments	NICE response
Royal College of Physicians	Not answered	We are happy to support this proposal.	Thank you.
Department of Health and Social Care	Not answered	I wish to confirm that the Department of Health and Social Care has no substantive comments to make, regarding this consultation.	Thank you.
Royal College of Paediatrics and Child Health	Yes	Needs to include information around RMOC.	Thank you for your comment. During this surveillance review, we noted that the advisory outputs of Regional Medicines Optimisation Committees (RMOCs) are aimed at groups who will be involved in local formulary decision-making. As such, we will refresh <a href="#">recommendation 1.1.2</a> to include regional decision-making groups, such as the RMOCs.

*Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees*

Royal College of Nursing	Yes	All responses received agreed with the proposal not to update the guideline. It is still fit for purpose and meets the need of colleagues developing local guidelines.	Thank you.
<b>Do you have any comments on areas excluded from the scope of the guideline?</b>			
<b>Stakeholder</b>	<b>Overall response</b>	<b>Comments</b>	<b>NICE response</b>
Royal College of Physicians	Not answered	No comments provided.	Thank you.
Department of Health and Social Care	Not answered	No comments provided.	Thank you.
Royal College of Paediatrics and Child Health	Yes	No information around extrapolation of medicines for children from adults, which has the implication to delay useful medicines for children. Some information on this in formularies would be beneficial.	Thank you for your comment regarding the addition of information on the extrapolation of medicines for children from adults. Whilst we acknowledge that this may be beneficial, the nature of the local formulary will be dependent on the type of organisation and care provided. The guideline development group noted that there was evidence of local variation in the medicines covered by different formularies, with some organisations operating local formularies and other organisations developing separate formularies for specialised areas of care. The guideline therefore aims to provide good practice recommendations to support the development of local formularies that reflect local needs, reduce variation in prescribing and allow rapid uptake of innovative treatments. Additionally, no evidence was identified during this surveillance review to indicate that detailed guidance on this issue should be incorporated into the guideline.

*Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees*

Royal College of Nursing	No	No comments provided.	Thank you.
<b>Do you have any comments on equalities issues?</b>			
<b>Stakeholder</b>	<b>Overall response</b>	<b>Comments</b>	<b>NICE response</b>
Royal College of Physicians	Not answered	No comments provided.	Thank you.
Department of Health and Social Care	Not answered	No comments provided.	Thank you.
Royal College of Paediatrics and Child Health	Not answered	No comments provided.	Thank you.
Royal College of Nursing	No	No comments provided.	Thank you.

© NICE 2019. All rights reserved. Subject to [Notice of rights](#).

*Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees*